In recent years there has been great interest in determining synergistic drug combinations. A difficulty, however, is that the number of different possible schedules increases combinatorially when more than one drug is considered, so it is very hard to know what schedules should be tested. Physiomics, a computational biology company based in Oxford UK, has therefore developed a predictive PK-PD "Virtual Tumour" model that allows us to rationally design schedules for drug combinations [1]. In this poster, we show how the Virtual Tumor was used to predict and optimize a gemcitabine-docetaxel combination.
Gemcitabine Docetaxel
The two drugs have different mechanisms of action, and lead to cell progression delay in different phases of the cell cycle. We therefore sought a schedule that would maximize the effect of the two drugs through cell synchronization, timing effects and PK time course profiles. In particular, we focused on the sequence and offset time between the two drug injections. By using the Virtual Tumor, it was possible to scan a high number of drug injection possibilities and predict which regimens could lead to the best synergy between the two drugs.
We identified 3 schedules that were of particular interest ( Figure 4 ):
• one schedule expected to result in the worst synergy: Gemcitabine then Docetaxel 4 hours later;
• two schedules expected to result in better synergy: Gemcitabine then Docetaxel 12 hours apart and Docetaxel then Gemcitabine 10 hours apart. Four cycles of drug administration were made for each regimen. Total drug dose was constant in all regimens (each dose: Gemcitabine 60 mg/kg, Docetaxel 7.5 mg/kg).
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PK and PD study of Gemcitabine and Docetaxel for Virtual Tumor calibration
In order to accurately model drug effect on cell cycle progression and calibrate the Virtual Tumor, we generated experimental PD and PK data obtained from single drug injection. Tumor sample analysis was done at different time points after dosing (from 0 to 72 hours, 4 mice per time point).
Pharmacodynamic data Figure 2 shows detection of phospho-histone H3 and topoisomerase II in O.C.T embedded tumor samples by immunohistochemistry. PD model was calibrated using these IVTI data: these helped understand the effect of each drug on MX-1 cell-cycle progression and calibrate the timing-related effect of each drug. 
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The 'Virtual Tumour' (Figure 1 ) is a sophisticated computer model that simulates tumour cell division and the effect of antineoplastic drugs, taking into consideration the differences between proliferative cells and those that are part of the necrotic core. The complexity of the model is deliberately constrained so that it can be parameterised with data that is usually produced during drug development. This data includes PK data for the drug, biomarkers showing the cell population response, and xenograft growth measurements showing how tumour growth is affected. This technology provides a rationale for designing an appropriate schedule, and allows our partners to prioritise the most effective drug combinations. The three schedules were experimentally tested in xenograft models, along with no-drug or single-drug treatment controls (Figures 5 & 6) .
Experimental methods
Pharmacokinetic data Docetaxel and gemcitabine levels were determined in plasma and frozen tumor samples using HPLC/MS-MS method. Calibrated PK models for each drug were samples using HPLC/MS-MS method. Calibrated PK models for each drug were built for use in Virtual Tumor (Figure 3) .
We have demonstrated that the Virtual Tumor could be used to predict the outcome of various gemcitabine -docetaxel combination regimens and to optimize the delivery schedule. Using PD and PK data that can be gathered during the development of a drug, this could lead to dramatic improvement in its usage, efficacy and prevent loss of synergy due to timing issues. This technology can be used to design new regimens with proprietary compounds as well as standard of care, small molecules or biotherapeutical agents; help test possible schedules for combinations of different drugs that would be effectively impossible to investigate experimentally; and allow prioritisation of the most effective drug combinations. Virtual Tumor allowed us to predict a combination regimen~50% more efficient than another predicted regimen that was lacking synergy. Furthermore, this level of efficacy could be obtained with a lower dose of docetaxel than typically used in xenograft studies (7.5 mg/kg vs 10 mg/kg). Finally, toxicity was not higher in the more efficient combinations, as shown in mean body weight plots. This shows how critical timing can be when administrating drugs having different mechanisms of action and how predictive models could be used for optimization. 
